Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial

• Published in: JAMA : the journal of the American Medical Association Vol. 330; no. 11; pp. 1042 - 1053
• Main Authors: Nicholls, Stephen J, Nissen, Steven E, Fleming, Cynthia, Urva, Shweta, Suico, Jeffrey, Berg, Paul H, Linnebjerg, Helle, Ruotolo, Giacomo, Turner, P. Kellie, Michael, Laura F
• Format: Journal Article
• Language: English
• Published: United States American Medical Association 19.09.2023
• Subjects: Administration, Oral; Adolescent; Adult; American Indian or Alaska Native; Aorta; Aortic stenosis; Apolipoproteins; Apoprotein(a) - antagonists & inhibitors; Arteriosclerosis; Atherosclerosis; Biomarkers; Black or African American; Cardiovascular Agents - administration & dosage; Cardiovascular Agents - adverse effects; Cardiovascular Agents - therapeutic use; Clinical significance; Clinical trials; Dosage; Dose-Response Relationship, Drug; Double-Blind Method; Double-blind studies; Female; Females; Health services; Humans; Hypolipidemic Agents - administration & dosage; Hypolipidemic Agents - adverse effects; Hypolipidemic Agents - therapeutic use; Inhibitors; Lipoprotein(a) - antagonists & inhibitors; Male; Middle Aged; Online First; Oral administration; Pharmacodynamics; Pharmacokinetics; Placebos; Plasma levels; Plasminogen; Preliminary Communication; Racial Groups; Reduction; Safety; White; Young Adult; United States > US; Alaska

IMPORTANCE: Lipoprotein(a) (Lp[a]) is associated with atherosclerotic disease and aortic stenosis. Lp(a) forms by bonding between apolipoprotein(a) (apo[a]) and apo B100. Muvalaplin is an orally administered small molecule that inhibits Lp(a) formation by blocking the apo(a)-apo B100 interaction whi...